A PHASE 1, OPEN-LABEL, RANDOMIZED, 2-TREATMENT SINGLE-DOSE, CROSS-OVER STUDY, 2-PART DESIGN TO EVALUATE THE BIOEQUIVALENCE AND TOLERABILITY OF TESTOSTERONE CYPIONATE FOLLOWING INTRAMUSCULAR (IM) INJECTION IN HEALTHY HYPOGONADAL MALE SUBJECTS
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Testosterone cipionate (Primary)
- Indications Hypogonadism
- Focus Pharmacokinetics
- Acronyms DEPO-T-BE-STUDY
- Sponsors Pfizer
Most Recent Events
- 23 Mar 2021 Results of post-hoc analysis of two studies this and other presented at the 103rd Annual Meeting of the Endocrine Society.
- 11 May 2020 Status changed from recruiting to completed.
- 07 Feb 2020 Planned number of patients changed from 54 to 72.